DONESHA OBASEKI: Open Payments
NPI 1063296671 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$589 in 24 payments from 9 companies in 2025. Trend: 2023 $629 · 2024 $1,443 · 2025 $589
Food & beverage: $589
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $154 |
| Teva Pharmaceuticals USA, Inc. | 4 | $104 |
| ABBVIE INC. | 4 | $101 |
| Janssen Pharmaceuticals, Inc | 2 | $64 |
| Lundbeck LLC | 2 | $58 |
| Alkermes, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: INGREZZA, VRAYLAR, UZEDY, REXULTI, ARISTADA, CAPLYTA, SPRAVATO, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
